5-Amino-1MQ
Small-molecule NNMT inhibitor for adipose and metabolic research
5 mg vial · 50 mg vialpeptide · also known as LY3437943, triple agonist
A triple agonist of the GIP, GLP-1 and glucagon receptors.
Retatrutide · 10 mg · Lyophilised vial
peptide · also known as LY3437943, triple agonist
A triple agonist of the GIP, GLP-1 and glucagon receptors.
In stock
Retatrutide (LY3437943) is a synthetic peptide that activates three receptors involved in energy balance: GIP, GLP-1 and glucagon. It has been studied in clinical trials and is supplied here as a research reagent in vials of 10 mg and 15 mg and as a 40 mg QuickPen.
PubMed records selected for relevance to the compound. They describe published research, not outcomes or uses.
| Compound | Retatrutide (LY3437943, triple agonist) |
|---|---|
| Type | Peptide |
| Selected presentation | 10 mg · Lyophilised vial |
| Form | Lyophilised powder in a sealed glass vial |
| Fill volume and concentration | Not applicable (lyophilised) |
| Label | CELVIVE wordmark, compound name, amount, "Purity: >99%", "For research use only" |
| Storage | -20 °C for long-term storage; 2 to 8 °C for under three months; away from light |
| Certificate of analysis | Not yet published online. Request for a batch |
| Research areas | Metabolic & GLP research |
| All presentations | 10 mg lyophilised vial · € 85.00 15 mg lyophilised vial · € 110.00 40 mg QuickPen · € 235.00 |